DIABETES E O FUTURO DO TRATAMENTO DIABETES AND THE FUTURE OF TREATMENT
作者： José Luis Medina , Selma Souto , Joana Ferreira
DOI:
关键词:
摘要: prevalence of diabetes has been increasing alarmingly, with a significant proportion cases remaining undiagnosed. The pharmaceutical industry, research laboratories and technology have key role in finding new solutions that optimize treatment reduce complications, improvement quality life. This review aims to briefly present the novelties hopes pharmaceutical, biological technological field. Regarding insulin therapy, intensive is currently being made on "smart insulins", future repercussions, biosimilar versions glargine are also developed. In future, nanotechnology could revolutionize diabetes, for its application drug oral insulin, monitoring blood glucose. For type 2 molecules developed existing drugs modified order increase duration action, improve combination known adverse effects. Moreover, therapeutic approaches further developed, including adipose tissue transplant/regeneration strategies, reprogramming different cell types, "digital pancreas" use digital technologies control glycaemia. Investment programs important not only find suitable means prevention cure, but develop better strategies. It can be considered intervention concerted various fields,
farmacoterapia.pt 参考文章(40)
Thyra de Jongh, Ipek Gurol-Urganci, Vlasta Vodopivec-Jamsek, Josip Car, Rifat Atun, Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database of Systematic Reviews. ,vol. 12, ,(2012) , 10.1002/14651858.CD007459.PUB2
Vivian A. Fonseca, Yehuda Handelsman, Bart Staels, Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism. ,vol. 12, pp. 384- 392 ,(2010) , 10.1111/J.1463-1326.2009.01181.X
Subhadra C. Gunawardana, Therapeutic value of brown adipose tissue: Correcting metabolic disease through generating healthy fat. Adipocyte. ,vol. 1, pp. 250- 255 ,(2012) , 10.4161/ADIP.21042
M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, J. J. Meier, Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. ,vol. 54, pp. 10- 18 ,(2011) , 10.1007/S00125-010-1896-4
F. Andreelli, C. Amouyal, C. Magnan, G. Mithieux, What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes & Metabolism. ,vol. 35, pp. 499- 507 ,(2009) , 10.1016/S1262-3636(09)73456-1
C Shivaprasad, Sanjay Kalra, None, Bromocriptine in type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. ,vol. 15, pp. 17- ,(2011) , 10.4103/2230-8210.83058
Nigel Irwin, Peter R. Flatt, Therapeutic potential for GIP receptor agonists and antagonists. Best Practice & Research Clinical Endocrinology & Metabolism. ,vol. 23, pp. 499- 512 ,(2009) , 10.1016/J.BEEM.2009.03.001
Morwenna Kirwan, Corneel Vandelanotte, Andrew Fenning, Mitch J Duncan, Diabetes Self-Management Smartphone Application for Adults With Type 1 Diabetes: Randomized Controlled Trial Journal of Medical Internet Research. ,vol. 15, pp. 1- 14 ,(2013) , 10.2196/JMIR.2588
Gillian M. Keating, Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus Drugs. ,vol. 73, pp. 575- 593 ,(2013) , 10.1007/S40265-013-0051-1
Ersin Akinci, Anannya Banga, Katie Tungatt, Joanna Segal, Daniel Eberhard, James R. Dutton, Jonathan M. W. Slack, Reprogramming of Various Cell Types to a Beta-Like State by Pdx1, Ngn3 and MafA PLOS ONE. ,vol. 8, ,(2013) , 10.1371/JOURNAL.PONE.0082424